Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 103
- Registration Number
- NCT00770536
- Locations
- 🇧🇪
Research Site, Wilrijk, Belgium
Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00757042
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 144
- Registration Number
- NCT00752570
A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT00752414
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00721734
- Locations
- 🇺🇸
University of California- San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT00686335
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Amgen
- Registration Number
- NCT00661921
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 350
- Registration Number
- NCT00650078
- Locations
- 🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Klinika Reumatologii i Ukladowych Chorób Tkanki Lacznej, Lublin, Poland
🇭🇺Debreceni Egyetem, III. Belgyógyászati Klinika, Reumatológiai Tanszék, Debrecen, Hungary
🇭🇺MÁV Kórház Szolnok, Reumatológiai Osztály, Szolnok, Hungary
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 179
- Registration Number
- NCT00613106
- Locations
- 🇺🇸
PRA International, San Diego, California, United States
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT00603642
© Copyright 2024. All Rights Reserved by MedPath